CN108712866A - 健脑食品或健脑饮品与其施用方法 - Google Patents
健脑食品或健脑饮品与其施用方法 Download PDFInfo
- Publication number
- CN108712866A CN108712866A CN201780013861.5A CN201780013861A CN108712866A CN 108712866 A CN108712866 A CN 108712866A CN 201780013861 A CN201780013861 A CN 201780013861A CN 108712866 A CN108712866 A CN 108712866A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- brain
- folic acid
- drink
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 61
- 210000004556 brain Anatomy 0.000 title claims abstract description 58
- 230000001256 tonic effect Effects 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 102
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 98
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 56
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 56
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 56
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 56
- 235000019152 folic acid Nutrition 0.000 claims abstract description 52
- 239000011724 folic acid Substances 0.000 claims abstract description 52
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960000304 folic acid Drugs 0.000 claims abstract description 51
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 50
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 48
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 48
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 230000002650 habitual effect Effects 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 206010012289 Dementia Diseases 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 26
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 16
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 16
- 230000036765 blood level Effects 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 9
- 238000011160 research Methods 0.000 abstract description 5
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000009467 reduction Effects 0.000 description 10
- 230000035622 drinking Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 230000008447 perception Effects 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000034189 Sclerosis Diseases 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 210000001353 entorhinal cortex Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 210000004326 gyrus cinguli Anatomy 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000869 occipital lobe Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940046001 vitamin b complex Drugs 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000541656 Carex marina Species 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- -1 cobalt sulfite amine Chemical class 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 229960005452 cobamamide Drugs 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001747 pteroyl group Chemical group [H]C1=C([H])C(C(=O)[*])=C([H])C([H])=C1N([H])C([H])([H])C1=C([H])N=C2N([H])C(N([H])[H])=NC(=O)C2=N1 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000011890 sandwich Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7056—Vitamin B8 Folic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/706—Vitamin B12
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pediatric Medicine (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
研发一种预防、减缓因摄取酒精造成的脑萎缩的健脑食品、健脑饮料。一种为了预防非痴呆症的习惯性饮酒者,也就是健全者饮酒造成的脑容积减少,且作为有效成分含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品,其特征在于,作为有效成分含有0.4‑0.8mg的叶酸、10‑20mg的维生素B6、0.25‑0.5mg的维生素B12。
Description
技术领域
本发明涉及一种健脑食品或健脑饮品,和其施用方法,具体地说,特别是涉及一种成分中含有叶酸、维生素B6和维生素B12的食品或饮品,和其施用方法。
背景技术
根据厚生劳动省研究部门推算(2008年),一年之中饮酒造成的社会损失高于4兆1493亿日圆。其中包括治疗肝脏疾病、中风、癌症等疾病与外伤的医疗费用1兆226亿日圆、因疾病与死亡造成的劳动损失和生产力下降等雇用损失3兆947亿日圆,以及用于汽车车祸、犯罪、社会保险的283亿日圆。加上家庭破灭与其对孩童造成的影响等难以换算成实际金额的问题,酒精相关问题造成非常巨大的社会损失,对健康造成的影响更是严重。
长期的饮酒习惯对会健康造成各种危害已广为人知。一般而言口腔癌、口咽癌、喉癌、食道癌、肝癌、大肠癌等消化系统癌症较为人所知,其中由酒精性肝炎与肝硬化恶化导致的肝癌等肝脏相关的疾病众所皆知。另外,关于以数值监控肝功能时所用的指标也有相当程度的研究并受到广泛地运用。也因此,有关饮酒对健康造成的危害的应对与预防至今为止都以肝脏为主要对象。
另一方面,饮酒习惯对脑部造成的伤害(脑萎缩)在近年来也逐渐受到注目。
2008年时有研究报告指出,即使是被视为适量的酒精摄取量(20g/日)也有可能造成脑萎缩(“Archives of Neurology”2008,65(10),1363-1367)。由此见解可以发现,在思考如何预防与应对饮酒对健康造成的危害时,除了肝功能障碍指标所用的GOT与GPT的肝细胞酶的血中浓度外,脑萎缩也可以是饮酒导致的脑部伤害的指标。因此,通过监控习惯性饮酒对脑容积数值造成的影响,并将其运用在研发出预防或减缓脑萎缩的食品·饮品非常受到期待。然而,摄取酒精所造成的脑萎缩,其机制仍然不明,因此要减缓这样的脑萎缩可以说非常困难。
本发明的发明者运用在脑部检查时,通过在日本健检中相当受欢迎的MRI执行的脑部容积检测方法研究饮酒量与脑萎缩之间的关联性。研究结果发现,随着饮酒量升高全脑容积比便跟着下降,也就是说脑萎缩正在恶化。于是本发明的发明者利用MRI所得的脑容积数值调查脑萎缩与血液中各种代谢物的浓度的关联,并试图找出摄取酒精时引发脑萎缩的因子。
血液中包含各种代谢物,其浓度的变化与各式疾病的发生息息相关。其中的同型半胱氨酸是必要胺基酸的蛋氨酸的代谢中间产物。如同型半胱氨酸的血中浓度增加,血管内皮细胞中便会产生活性氧,并且增进动脉硬化是广为人知的。另外,同型半胱氨酸通过抑制一氧化氮的产生使血小板凝聚,最终引发血栓生成也广为人知。甚至也有研究报告指出,因为同型半胱氨酸的增加造成的动脉硬化与血栓生成会引发脑循环障碍,最终导致脑梗塞(“Stroke”2001;32:1116-1119)。
抑制同型半胱氨酸数值的成分中,以叶酸、维生素B6与维生素B12较为人所知。叶酸与维生素B6能促进同型半胱氨酸代谢为蛋氨酸,维生素B12则可以促进同型半胱氨酸分解为半胱氨酸。
专利文献1公开一种合成物,其含有维生素B6、维生素B12、由1种或2种以上的叶酸而成的维生素B群、芝麻素。
专利文献2公开一种合成物,其主要成分是蔓长春花提取物(别名小蔓长春花提取物)与银杏叶提取物,另外包含二十二碳六烯酸、卵磷脂的其中一种或以上、维生素B6、维生素B12与叶酸。
所述专利文献1-2公开的发明中,除叶酸、维生素B6、维生素B12外,通过添加芝麻素与二十二碳六烯酸降低血液中的同型半胱氨酸数值,并针对阿尔兹海默病的症状尝试恢复脑部机能。
所述专利文献1-2中是针对阿尔兹海默病的脑部机能恢复的报告,非痴呆症的健全者因为习惯性摄取酒精而对脑萎缩造成的影响完全未被提及。
另外,根据非专利文献3-5中的记载,为预防70岁以上的高龄者因为MCI(轻度认知障碍)造成脑萎缩,提供叶酸、维生素B6、维生素B12,但却没有将非痴呆症也非MCI的习惯性饮酒者,也就是健全者作为对象。
现有技术文献
专利文献
专利文献1:日本特开2009-173640号公报
专利文献2:日本特开2004-168699号公报
非专利文献
非专利文献1:“Archives of Neurology”2008,65(10),1363-1367
非专利文献2:“Stroke”2001;32:1116-1119
非专利文献3:“PloS ONE”2010年,Vol.5,Issue 9,e12244,pp.1-10
非专利文献4:Proceeding of the National Academy of Science(PNAS)2013年,Vol.110,No.23,pp.9523-9528
非专利文献5:“Int.J.Geriatr.Psychiatry”2012年,Vol.27,pp.592-600
发明内容
要解决的技术问题
本发明的发明者致力于找出摄取酒精时引发脑萎缩的因子,以习惯性摄取大量酒精者为对象,监控以MRI测得的脑容积数值的同时,测量并分析摄取大量酒精者血液中的各种因子后,着眼于同型半胱氨酸数值与脑萎缩之间的关联性。然后,通过涉及同型半胱氨酸代谢的亚甲基四氢叶酸还原酶(以下称MTHFR)的遗传多样性,看出了叶酸、维生素B6、维生素B12的施用效果不尽相同。此外,如同许多减重商品因为腰围与BMI能够判断减重效果而被研发一般,决意着手研发预防与减缓脑萎缩的食品·饮品。在受测者施用本发明前,同型半胱氨酸的血中浓度在12mmol/ml以下,加上维生素B12的血中浓度在435-1000pg/ml的条件下(Δ条件),将能够有效抑制同型半胱氨酸增加的叶酸、维生素B6与维生素B12加入食品与饮品中,能够抑制同型半胱氨酸增加,进一步说,就是成功研发出能够预防摄取酒精造成的脑萎缩的食品或饮品。
技术手段
权利要求1的发明涉及一种为了预防非痴呆症的习惯性饮酒者,也就是健全者饮酒造成的脑容积减少,且作为有效成分含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品,其特征在于,作为有效成分含有0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12。
权利要求2的发明涉及一种为了预防非痴呆症的习惯性饮酒者,也就是健全者饮酒造成的脑容积减少,且作为有效成分含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品的使用,其特征在于,所述健全者在摄取所述健脑食品或所述健脑饮品前,同型半胱氨酸的血中浓度在12mmol/ml以下,加上维生素B12的血中浓度在435-1000pg/ml之间,并含有0.4-0.8mg的所述叶酸、10-20mg的所述维生素B6、0.25-0.5mg的所述维生素B12。
权利要求3的发明涉及根据权利要求2所述的使用,其特征在于,所述健全者的MTHFR的SNP(单核苷酸多态性)的基因型为CC型或CT型。
此外,本权利要求中,「健全者」指的是不患有痴呆症的习惯性饮酒者(习惯每日饮酒者)。
本发明的有益效果
根据权利要求1的发明,通过将0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12作为有效成分加入食品或饮品中,可以有效降低摄取所述食品或饮品者的血液中的同型半胱氨酸数值。由此,能达到抑制健全者(不患有痴呆症的习惯性饮酒者)因为长期摄取酒精造成的脑容积减少的效果。
根据权利要求2的发明,通过事先调查健全者的同型半胱氨酸与维生素B12的血中浓度,可以预测本发明的健脑食品与健脑饮品的效果,也就可以更有效率地促进有饮酒习惯者的健康。
根据权利要求3的发明,通过事先调查健全者的MTHFR的SNP类型(CC型、CT型、TT型),可以预测本发明的健脑食品与健脑饮品的效果,也就可以更有效率地促进有饮酒习惯者的健康。
附图说明
图1为叶酸、维生素B6、维生素B12与同型半胱氨酸代谢之间关系的示意图。
图2为血液中同型半胱氨酸浓度的A群(安慰剂群)对B群(健脑食品服用群)的比较示意图。
图3A所示为,将血液中同型半胱氨酸浓度的降低与脑萎缩减缓反应分层后的结果。A群为安慰剂群,B群为健脑食品服用群。组别I至组别III分别代表,组别I:同型半胱氨酸浓度未降低的组别,组别II:同型半胱氨酸浓度有降低,脑萎缩却没有减缓的迹象,组别III:同型半胱氨酸浓度有降低,脑萎缩也有减缓的迹象。
图3B为A群(安慰剂群)与B群(健脑食品服用群)中,所述组别I至组别III的数值的示意图。
图4A为针对MTHFR基因的SNP是CC型者,A群(安慰剂群)与B群(健脑食品服用群)中,所述组别I至组别III的数值的示意图。
图4B为针对MTHFR基因的SNP是CT型者,A群(安慰剂群)与B群(健脑食品服用群)中,所述组别I至组别III的数值的示意图。
图4C为针对MTHFR基因的SNP是TT型者,A群(安慰剂群)与B群(健脑食品服用群)中,所述组别I至组别III的数值的示意图。
图5A为在满足受测者施用本发明前,同型半胱氨酸的血中浓度在12mmol/ml以下,加上维生素B12的血中浓度在435-1000pg/ml(Δ条件)的条件的情况下,A群(安慰剂群)与B群(健脑食品服用群)中,全脑容积比的比较示意图。
图5B为未满足Δ条件的情况下,A群(安慰剂群)与B群(健脑食品服用群)中,全脑容积比的比较示意图。
图6为受测者(非痴呆症的习惯性饮酒者,也就是健全者)在满足Δ条件的情况下,每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12的药剂,持续9个月后脑容积增加的部位的示意图。
图7为受测者(非痴呆症的习惯性饮酒者,也就是健全者)在满足Δ条件的情况下,摄取本发明的感觉调查结果的示意图。受测者每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12,持续9个月后进行感觉调查。
具体实施方式
本说明书中,「健全者」指的是不患有痴呆症的习惯性饮酒者(习惯每日饮酒者)。
本发明是一种为了抑制体内同型半胱氨酸浓度增加伴随的脑萎缩,并在成分中含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品,一天可以服用或食用一次以上,所述叶酸、维生素B6、维生素B12的每日摄取量可以为叶酸(0.4-0.8mg)、维生素B6(10-20mg)、维生素B12(0.25-0.5mg)。
本发明的食品·饮品中所使用的叶酸可以为蝶酰聚谷氨酸、蝶酰单谷氨酸、或是由它们混合而成。
本发明的食品·饮品中所使用的维生素B6可以为吡哆醇、吡哆醛、吡哆胺的磷酸酯型态,也就是吡哆醇-5-磷酸(PNP)、吡哆醛-5-磷酸(PLP)、吡哆胺-5-磷酸(PMP)或是由它们混合而成。
本发明的食品·饮品中所使用的维生素B12可以为羟钴胺、腺苷钴胺、甲钴胺、氰钴胺、亚硫酸钴胺或是由它们混合而成。
根据所述食用或服用方法,食用或服用含有0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12的健脑食品或健脑饮品时,摄取所述食品或饮品者能有效降低血液中的同型半胱氨酸数值。由此,可以有效抑制因为长期摄取酒精所造成的脑萎缩(见图3B)。这些成分的含量是一般维生素营养剂的4至100倍。发明者知道于本发明中加入大量叶酸、维生素B6、维生素B12能够有效达到发明的效果。
如上所述,食用本发明的健脑食品或健脑饮品,叶酸、维生素B6、维生素B12的每日摄取量可以为0.8mg、20mg、0.5mg。MTHFR为CT型时,成分中含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品能有效抑制因为同型半胱氨酸浓度升高造成的脑萎缩,CC型效果不彰,TT型则没有抑制的效果(见图4A-C)。
添加进饮品时,由于长期保存可能导致成分分解,理想的量为所述的1.8倍,然而1.8倍量将会使含量超过营养表示基准规定的上限值。因此实际的含量在考虑这些条件的状况下决定即可。MTHFR为CT型时,成分中含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品能有效抑制因为同型半胱氨酸浓度升高造成的脑萎缩,CC型效果不彰,TT型则没有抑制的效果(见图4A-C)。
<通过叶酸、维生素B6、维生素B12控制同型半胱氨酸浓度>
蛋白质经过消化吸收,分解为胺基酸后,会生成必要胺基酸的蛋氨酸。蛋氨酸于肝脏中被代谢,此时生成的代谢中间产物就是同型半胱氨酸(见图1)。
分解同型半胱氨酸时,叶酸、维生素B6、维生素B12是必要的。叶酸会通过将其代谢产物的5-甲基四氢叶酸代谢为四氢叶酸的过程,促进同型半胱氨酸代谢为蛋氨酸。在此过程中,四氢叶酸会二甲胺化,并生成5,10-甲基四氢叶酸。5,10-甲基四氢叶酸再由MTHFR还原,并生成5-甲基四氢叶酸。
维生素B12会促进同型半胱氨酸代谢为蛋氨酸。另外,维生素B6会使同型半胱氨酸分解为半胱氨酸。
<习惯性摄取酒精会通过叶酸、维生素B6、维生素B12使同型半胱氨酸数值上升,减少脑容积,也就是可能引发脑萎缩>
慢性且大量摄取酒精会改变肠胃的黏膜细胞的性质,并阻碍叶酸、维生素B6、维生素B12的吸收。此外,起因于摄取酒精的乙醛会促进叶酸、维生素B6、维生素B12的分解。其结果就是血液中的同型半胱氨酸浓度上升。
同型半胱氨酸的血中浓度增加会使血管内皮细胞中产生活性氧,并促进动脉硬化是众所皆知的。此外,同型半胱氨酸会抑制一氧化氮的产生进而促进血小板凝聚最终引发血栓生成也是广为人知的。甚至也有报告指出因为动脉硬化与血栓生成会引发脑循环障碍,最终导致脑梗塞。因此,可以说习惯性摄取酒精造成的同型半胱氨酸浓度上升会引发脑循环的低下,最终导致脑萎缩。
如上所述,习惯性摄取酒精会造成同型半胱氨酸数值的上升,并因此引发脑萎缩。而发明者看出大量投与叶酸、维生素B6、维生素B12能够有效分解同型半胱氨酸并降低同型半胱氨酸数值。将0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12添加至食品或饮品中,摄取所述食品或饮品者能有效降低血液中的同型半胱氨酸数值(见图2)。由此可以抑制长期摄取酒精造成的脑萎缩,并有效预防脑容积的减少。
实施例
以下说明是关于本发明适宜的实施例,然而本发明不限于说明书与附图的内容。
(实施例1.摄取健脑食品对脑萎缩影响的评价)
让非痴呆症患者(健全者)摄取本发明的健脑食品,对因酒精摄取引起的大脑萎缩的预防效果进行评价。
<实施方法>
对象为96名(男性48名、女性48名)健全者,通过随机双盲试验检测摄取健脑食品的效果。试验对象为年龄30-60岁(平均48.4岁)的健全者(几乎每日饮酒者),不吸烟且没有服用营养保健品,包含肝功能等健康状态都良好。
将受测者分为两群,A群服用安慰剂,B群则每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12的药剂。受测者分别于第0个月、第3个月、第9个月检查以下项目。
■脑部检查时,通过MRI检测脑部容积
■检测维生素B群等的血中浓度
■遗传多样性(SNP:MTHFR)的检查
遗传多样性检查只于第0个月时实施。
<结果>
首先比较AB群之间血液中的同型半胱氨酸浓度。其结果如图2所示,血液中的同型半胱氨酸浓度的变化率在服用药剂3个月后,B群相对A群有显著的下降。(A群0.0310±0.18467,n=47;B群-0.2355±0.16925,n=49)。
接着是此血液中的同型半胱氨酸浓度的减少对于脑萎缩影响的评价。为此将受测者分为三个组别,并针对血液中同型半胱氨酸浓度的降低与脑萎缩减缓反应进行分层。
组别I:同型半胱氨酸浓度未降低的组别
组别II:同型半胱氨酸浓度有降低,脑萎缩却没有减缓的迹象
组别III:同型半胱氨酸浓度有降低,脑萎缩也有减缓的迹象
此外,比较A群(安慰剂群)与B群(健脑食品服用群)中,上述组别I、II、III各组别的人数,并积和检验后,发现AB群之间有显著性差异(图3B)。也就是相对于A群,B群中组别III(同型半胱氨酸浓度有降低,脑萎缩的减缓也有减缓的迹象的组别)的比例有显著的增加(Mann-Whitney U检验:p<0.001)。
<考察>
由所述结果可以发现,通过每日摄取0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12可以有效降低血液中同型半胱氨酸的浓度。再者,因为此同型半胱氨酸浓度的降低,脑萎缩也有减缓的迹象。
(实施例2.摄取健脑食品对脑萎缩影响的评价、MTHFR带来的影响)
针对所述实施例1所得的资料,利用代谢同型半胱氨酸的限速酶的MTHFR的SNP的基因型(CC型:野生型、CT型:异型、TT型:同型)再次进行研究(见图4A-C)。首先将受测者依MTHFR的SNP之中3种不同的基因型分为3群(CC型、CT型、TT型)。接着针对各受测者群,进行和实施例1相同的分析(组别I、II、III的数值分布中AB群的比较)。其结果,CT型(异型)中组别I至组别III的数值分布偏差在AB群之间非常显著(Mann-Whitney U检验:p<0.001)(见图4B)。另一方面,CC型(野生型)中数值分布的偏差与CT型(异型)虽然有类似的倾向,数值分布的偏差在AB群之间却不显著(Mann-Whitney U检验:P=0.09)(见图4A)。也就是说MTHFR的CT型(异型)比起CC型(野生型),在摄取健脑食品后减缓脑萎缩的效果较好。MTHFR的活性在TT型(同型)中活性较低,因此即使摄取健脑食品也没有显著的减缓脑萎缩的效果(Mann-Whitney U检验:p=0.478)(见图4C)。
(实施例3.提供健脑食品减缓饮酒造成的脑萎缩的组别视为相同(Δ条件))
所述实施例1和2中使用MRI所得的脑容积检测的方法是,将受测者的脑映射到事先决定好大小的标准脑,在获得脑容积的概率分布后,再以逆映射获得各脑部容积的VBM(voxelbased morphometry)方法,然而健全者的脑容积每年的变化量低至1-2ml,因此需要更准确的检测方法。
于是,本实施例中使用不透过标准脑,而是通过直接比较受测者脑部在两个时间点上脑容积的不同的TBM(tensor based morphometry)方法进行分析。也就是说,针对预防摄取酒精造成的脑萎缩的效果,比较持续摄取本发明9个月前后的全脑容积进行分析。具体地说通过以下方法进行分析。
<实施方法>
对象为96名(男性46名、女性50名)健全者,通过随机双盲试验检测摄取健脑食品的效果。试验对象为年龄30-60岁(平均48.4岁)的健全者(几乎每日饮酒者),不吸烟且没有服用营养保健品,包含肝功能等健康状态都良好。
将受测者分为两群,A群服用安慰剂,B群则连续9个月每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12的药剂,找出A群与B群间脑萎缩得到减缓的组别的条件。
如此可以发现,满足在施用健脑食品前,同型半胱氨酸的血中浓度在12mmol/ml以下且维生素B12在435-1000pg/ml的范围内条件(Δ条件)的组别中(38名:男性13名,女性25名),A群与B群的全脑容积比的平均值上,B群比起A群有显著的增加(图5A:A群0.99801±0.00310,n=24、B群1.00041±0.002476,n=14;t检验,P=0.018)。
相反地,未满足Δ条件的组别中(58名:男性33名,女性25名)并没有显著性差异(图5B:A群0.99823±0.00049,n=23,B群0.99711±0.00057,n=35;t检验,P=0.172)。
由此可知,习惯性摄取酒精者之中,脑萎缩得到减缓的组别的条件为,施用健脑食品前,同型半胱氨酸的血中浓度在12mmol/ml以下且维生素B12在435-1000pg/ml的范围内(Δ条件)。
(实施例4:Δ条件与MTHFR带来的影响)
关于实施例3所得的资料(关于Δ条件的资料),针对其与MTHFR的SNP的基因型(CC型:野生型、CT型:异型、TT型:同型)之间的关系再次进行研究。满足Δ条件中的38名,CC型为5名、CT型为32名、TT型为一名,可以说满足Δ条件的健全者几乎都是CC型或CT型。
(实施例5:通过施用本发明后容积增加的脑部位)
将满足Δ条件的受测者分为两群,A群服用安慰剂,B群则每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12的药剂,在第9个月以TBM方法进行脑部容积检测。
其结果,B群比起A群,容积有显著增加的脑部位如以下所述(见图6)。
1:左前扣带回
2:左岛叶前部
3:右中岛盖部
4:右内嗅皮质
5:右下枕叶脑回
6:左中央沟前侧脑回中部
7:左额上回中部
8:布罗德曼44区
9:右海马旁回
10:右顶岛盖
11:右后眶额回
12:右中央沟前侧脑回
13:左颞平面
14:右额上回
15:左运动辅助区
16:布罗德曼45区
17:左颞横回
由此可知,本发明可有效增加所述脑部位的容积。
(实施例6.摄取健脑食品的感觉调查)
将受测者分为两群,A群服用安慰剂,B群则每日服用含有0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12,持续9个月后进行感觉调查。
调查时的提问为以下11则
1.服用药剂前后身体状况有改变
2.饮酒后较不容易醉
3.身体的倦怠感消失或减轻
4.运动后较不易疲劳
5.较容易入睡
6.变得能够熟睡
7.食欲变好
8.排便状况改善
9.皮肤更有光泽
10.上妆效果变好
11.较不容易心情低落
受测者根据所述提问,毫无感觉答1,几乎没有感觉答2,稍微有感觉答3,有感觉答4,非常有感觉答5。将评价结果数值分布后,再从数值分布中算出平均值、标准差与平均值的标准误。另外,通过以t检验算出P值来确认各提问的A群与B群间是否有显著的差异。其结果表示于图7。
根据感觉调查的结果,将未满足Δ条件的组别中A群与B群比较后,发现在所有提问中并没有显著性差异(无附图)。
相对于此,在满足Δ条件的组别中,提问3、7、8、10、11中P<0.05的情况下A群与B群间有显著的差异,提问1、4则是在P<0.10情况下有显著性差异(见图7)。
由此结果可以发现,满足Δ条件且摄取本发明的健脑食品的受测者在感觉调查中表现出显著的阳性反应。相对地,在所述感觉调查中表现出显著的阳性反应的受测者有非常高的机率满足Δ条件。
本发明的健脑食品的例子有,营养保健品、食疗食品、食用油脂、奶油、干酪、奶粉、肉类制品、加工水产食品、加工蔬菜与加工水果、油炸豆腐、冻豆腐、蒟蒻、豆腐、纳豆、加工蛋、炖咖里或高汤原汁、茶泡饭的海苔、拌饭素、小酱菜、食用蛋白质、甜面包、三明治、中华包子、汉堡、比萨、热狗、肉馅饼、调味料、辛香料、冰激凌的原料、雪酪的原料、谷物加工品、饺子、烧卖、寿司、章鱼小丸子、意大利饺、发酵粉、曲、酵母、焙粉、方便点心的原料、意大利酱、酒粕、食用面筋、食用粉类。通过0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12的添加量,能够得到预防所述脑萎缩的效果。配合量优选为0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12。
本发明的健脑饮品的例子有,食疗饮品、牛奶、乳酸饮料、乳酸菌饮料、发酵乳、奶粉(奶)、山羊奶、羊奶、炼乳、豆浆、茶、咖啡、可可亚、啤酒、软性饮料、果汁、蔬菜汁、日本酒、洋酒、水果酒、利久酒、中国酒、药酒。通过0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12的添加量,能够得到预防所述脑萎缩的效果。配合量优选为0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12。另外,添加进饮品时,由于长期保存可能导致成分分解,理想的量为所述的1.8倍,然而1.8倍量将会使含量超过营养表示基准规定的上限值。因此实际的含量在考虑这些条件的状况下决定即可。
所述食品的摄取方法为每日一次,份量为0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12,优选为0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12,另外所述摄取量也可以一日内分两次以上摄取。
所述饮品的摄取方法为每日一次,份量为0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12,优选为0.8mg的叶酸、20mg的维生素B6、0.5mg的维生素B12,另外所述摄取量也可以一日内分两次以上摄取。
实用性
本发明的健脑食品与健脑饮品能抑制同型半胱氨酸数值的上升,并有预防脑萎缩的效果,因此通过摄取·服用健脑食品与健脑饮品能有效促进习惯性饮酒者的健康。另外,依MTHFR的SNP的不同,健脑食品与健脑饮品对于脑萎缩的减缓效果也不同,因此事先检查SNP类型、同型半胱氨酸与维生素B12的血中浓度能够预测所述食品与饮品的效果,也就可以更有效率地促进有饮酒习惯者的健康。即使不事先检查SNP类型或血中浓度,也可以通过摄取所述食品与饮品后的感觉调查预测效果。
符号说明
1:左前扣带回
2:左岛叶前部
3:右中岛盖部
4:右内嗅皮质
5:右下枕叶脑回
6:左中央沟前侧脑回中部
7:左额上回中部
8:布罗德曼44区
9:右海马旁回
10:右顶岛盖
11:右后眶额回
12:右中央沟前侧脑回
13:左颞平面
14:右额上回
15:左运动辅助区
16:布罗德曼45区
17:左颞横回
Claims (3)
1.一种为了预防非痴呆症的习惯性饮酒者,也就是健全者饮酒造成的脑容积减少,且作为有效成分含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品,其特征在于,作为有效成分含有0.4-0.8mg的叶酸、10-20mg的维生素B6、0.25-0.5mg的维生素B12。
2.一种为了预防非痴呆症的习惯性饮酒者,也就是健全者饮酒造成的脑容积减少,且作为有效成分含有叶酸、维生素B6、维生素B12的健脑食品或健脑饮品的使用,其特征在于,所述健全者在摄取所述健脑食品或所述健脑饮品前,同型半胱氨酸的血中浓度在12mmol/ml以下,加上维生素B12的血中浓度在435-1000pg/ml之间,并含有0.4-0.8mg的所述叶酸、10-20mg的所述维生素B6、0.25-0.5mg的所述维生素B12。
3.根据权利要求2所述的使用,其特征在于,所述健全者的MTHFR的SNP的基因型为CC型或CT型。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016038284 | 2016-02-29 | ||
JP2016-038284 | 2016-02-29 | ||
JP2016-203890 | 2016-10-17 | ||
JP2016203890A JP6256888B2 (ja) | 2016-02-29 | 2016-10-17 | 健脳食品または健脳飲料およびこれらを投与する方法 |
PCT/JP2017/007573 WO2017150475A1 (ja) | 2016-02-29 | 2017-02-27 | 健脳食品または健脳飲料およびこれらを投与する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108712866A true CN108712866A (zh) | 2018-10-26 |
Family
ID=59742989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780013861.5A Pending CN108712866A (zh) | 2016-02-29 | 2017-02-27 | 健脑食品或健脑饮品与其施用方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210186971A1 (zh) |
EP (1) | EP3424350A4 (zh) |
JP (1) | JP6256888B2 (zh) |
KR (1) | KR20180117158A (zh) |
CN (1) | CN108712866A (zh) |
WO (1) | WO2017150475A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245360B1 (en) * | 1998-06-26 | 2001-06-12 | John S. Markowitz | Nutritional supplement |
CN1368853A (zh) * | 1999-06-29 | 2002-09-11 | 新西兰奶制品研究所有限公司 | 基于奶的预防性饮食添加剂 |
CN1483328A (zh) * | 2003-01-21 | 2004-03-24 | 曾庆友 | 预防心脑血管疾病的强化面粉 |
CN1781496A (zh) * | 2005-05-26 | 2006-06-07 | 钟健琳 | 生津生理水 |
CN1904023A (zh) * | 2005-07-26 | 2007-01-31 | 安徽省现代中药研究中心 | 一种保健葡萄饮品 |
CN101742926A (zh) * | 2007-06-26 | 2010-06-16 | N.V.努特里奇亚 | 用于改善脑功能的脂质组合物 |
WO2012001336A1 (en) * | 2010-07-01 | 2012-01-05 | Isis Innovation Limited | Treatment of cognitive disorders |
CN104223107A (zh) * | 2014-09-26 | 2014-12-24 | 洛阳华以生物工程有限公司 | 一种护肝解酒排毒的保健品 |
WO2015140545A1 (en) * | 2014-03-20 | 2015-09-24 | Isis Innovation Limited | Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004168699A (ja) | 2002-11-19 | 2004-06-17 | Fancl Corp | 脳機能改善組成物 |
JP5584411B2 (ja) | 2007-12-27 | 2014-09-03 | サントリーホールディングス株式会社 | ホモシステイン低下用組成物 |
-
2016
- 2016-10-17 JP JP2016203890A patent/JP6256888B2/ja active Active
-
2017
- 2017-02-27 CN CN201780013861.5A patent/CN108712866A/zh active Pending
- 2017-02-27 US US16/080,983 patent/US20210186971A1/en not_active Abandoned
- 2017-02-27 KR KR1020187027831A patent/KR20180117158A/ko not_active Application Discontinuation
- 2017-02-27 WO PCT/JP2017/007573 patent/WO2017150475A1/ja active Application Filing
- 2017-02-27 EP EP17759941.2A patent/EP3424350A4/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245360B1 (en) * | 1998-06-26 | 2001-06-12 | John S. Markowitz | Nutritional supplement |
CN1368853A (zh) * | 1999-06-29 | 2002-09-11 | 新西兰奶制品研究所有限公司 | 基于奶的预防性饮食添加剂 |
CN1483328A (zh) * | 2003-01-21 | 2004-03-24 | 曾庆友 | 预防心脑血管疾病的强化面粉 |
CN1781496A (zh) * | 2005-05-26 | 2006-06-07 | 钟健琳 | 生津生理水 |
CN1904023A (zh) * | 2005-07-26 | 2007-01-31 | 安徽省现代中药研究中心 | 一种保健葡萄饮品 |
CN101742926A (zh) * | 2007-06-26 | 2010-06-16 | N.V.努特里奇亚 | 用于改善脑功能的脂质组合物 |
WO2012001336A1 (en) * | 2010-07-01 | 2012-01-05 | Isis Innovation Limited | Treatment of cognitive disorders |
WO2015140545A1 (en) * | 2014-03-20 | 2015-09-24 | Isis Innovation Limited | Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species |
CN104223107A (zh) * | 2014-09-26 | 2014-12-24 | 洛阳华以生物工程有限公司 | 一种护肝解酒排毒的保健品 |
Non-Patent Citations (2)
Title |
---|
S. BLEICH: "Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism", 《NEUROSCIENCE LETTERS》 * |
余元勋: "《中国分子心脏病学》", 31 August 2015, 安徽科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
EP3424350A4 (en) | 2019-11-06 |
EP3424350A1 (en) | 2019-01-09 |
JP6256888B2 (ja) | 2018-01-10 |
US20210186971A1 (en) | 2021-06-24 |
KR20180117158A (ko) | 2018-10-26 |
WO2017150475A1 (ja) | 2017-09-08 |
JP2017153469A (ja) | 2017-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Piskin et al. | Iron absorption: factors, limitations, and improvement methods | |
Onyango | Dietary diversity, child nutrition and health in contemporary African communities | |
Cai et al. | Dietary patterns and their correlates among middle-aged and elderly Chinese men: a report from the Shanghai Men's Health Study | |
Edefonti et al. | Nutrient-based dietary patterns and the risk of oral and pharyngeal cancer | |
Wong | Iron deficiency anaemia | |
Cowin et al. | Association between composition of the diet and haemoglobin and ferritin levels in 18-month-old children | |
Anne Looker Ph D et al. | Vitamin-mineral supplement use: association with dietary intake and iron status of adults | |
Song et al. | The effect of coffee consumption on food group intake, nutrient intake, and metabolic syndrome of Korean adults—2010 KNHANES (V-1) | |
Hirayama et al. | Folate intake associated with lung function, breathlessness and the prevalence of chronic obstructive pulmonary disease | |
Jungjohann et al. | Eight-year trends in food, energy and macronutrient intake in a sample of elderly German subjects | |
Shim et al. | Ultra-processed food consumption and obesity in Korean adults | |
Tutelyan et al. | Russian regulations on nutraceuticals, functional foods, and foods for special dietary uses | |
Jausal et al. | Iron Consumption and Anemia in Adolescent Girls in Junior High School 1 Tanjung Sari, South Lampung | |
Golder et al. | Dietary intake and nutritional status of women and pre-school children in the Republic of the Maldives | |
Wood | Thiamin Status in Australia1 | |
CN111150011A (zh) | 一种营养型调味酱及其制备方法 | |
Gonzalez-Gross et al. | Folate status in Germany 1997–2000 | |
Uvere et al. | Complementary local foods for infants in developing countries | |
Densupsoontorn et al. | Micronutrient deficiencies in obese Thai children | |
CN108712866A (zh) | 健脑食品或健脑饮品与其施用方法 | |
Foster et al. | Implications of a plant-based diet on zinc requirements and nutritional status | |
Elhisadi | Food and nutrients intake among Libyan school children | |
Pobocik et al. | Nutritional and anthropometric assessment of a sample of pregnant women and young children in Palau | |
Sirikulchayanonta et al. | Do Thai women of child bearing age need preconceptional supplementation of dietary folate? | |
Kochetkova et al. | Fortification of food with micronutrients: development of methodological and regulatory framework in the Russian Federation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1259847 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181026 |
|
WD01 | Invention patent application deemed withdrawn after publication |